NAFLD and NASH Treatment in 2026: Lifestyle, FDA-Approved Therapy, and the Right Sequencing for Your Patient
.png)
Published on 20/04/2026
Updated NAFLD and NASH treatment in 2026: lifestyle, resmetirom, GLP-1 agonists, and when to consider fibrosis-targeted therapy.
A 54-year-old woman with type 2 diabetes, BMI 33, and incidentally discovered elevated ALT returns to your clinic. Her FibroScan shows CAP 320 dB/m and liver stiffness of 9.8 kPa. She has tried and abandoned two weight-loss programs. She asks if there is finally a pill for this. For the first time in the 30-year history of NAFLD research, the honest answer is yes - but only if you sequence it correctly.
The landscape of NAFLD and NASH treatment has fundamentally shifted since 2023. The nomenclature has moved - the field now formally prefers metabolic-associated steatotic liver disease (MASLD) - but more importantly, the therapeutic toolkit has expanded. Resmetirom received FDA approval in March 2024 as the first drug approved specifically for NASH with liver fibrosis, ending a long drought of failed trials. Simultaneously, GLP-1 receptor agonists have accumulated enough mechanistic and trial data to be used strategically. Despite this, the majority of patients with NAFLD/NASH still arrive in gastroenterology clinics without structured treatment plans - because the decision of who to treat, with what, and when remains genuinely complex. This post provides that framework.
Who Actually Needs Pharmacotherapy: Fibrosis Stage Is the Threshold That Matters
The central error in managing NAFLD NASH treatment is treating steatosis when you should be targeting fibrosis. Hepatic fat alone - even substantial steatosis - carries a relatively benign prognosis. It is the fibrosis stage that drives liver-related mortality, and this distinction should govern every treatment decision you make.
Per the 2023 AASLD NAFLD Practice Guidance, pharmacotherapy should be strongly considered in patients with biopsy-confirmed or non-invasively assessed NASH with fibrosis stage F2 or higher. Patients with F0-F1 fibrosis and no high-risk metabolic features are candidates for intensive lifestyle modification and monitoring - not drug therapy. This matters because it avoids overtreatment and focuses the newer, expensive pharmacological options where trial data actually demonstrate benefit.
Non-invasive fibrosis assessment has matured considerably. Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE/FibroScan) combined with serum markers (FIB-4 index) provides a reliable and practical staging pathway in most clinical settings. A FIB-4 < 1.30 in a patient under 65 has a high negative predictive value for advanced fibrosis - reassuring enough to defer biopsy. A FIB-4 > 2.67 warrants further imaging or biopsy to confirm advanced fibrosis before initiating targeted therapy. Biopsy remains the gold standard for cases where treatment eligibility depends on histological confirmation, particularly for resmetirom candidacy in current clinical practice.
Including a secondary keyword naturally: stratifying patients by the degree of metabolic-associated steatotic liver disease severity - not just steatosis alone - is what separates structured management from guesswork.
Clinical Scenario
A 48-year-old male with hypertension, HbA1c 7.4%, and BMI 31 presents with ALT persistently twice the upper limit of normal over 18 months. Ultrasound shows echogenic liver consistent with steatosis. His FIB-4 is 1.89 - indeterminate. FibroScan confirms LSM of 11.2 kPa with CAP of 295 dB/m. He has no history of alcohol excess and no alternative chronic liver disease etiology on workup.
Given his indeterminate FIB-4, elevated LSM suggesting F2–F3 fibrosis, and metabolic risk profile, a liver biopsy was pursued. Histology confirmed NASH with F3 fibrosis and NAS score of 5. He was started on resmetirom 100 mg daily alongside GLP-1 receptor agonist therapy for glycaemic control and weight reduction, and enrolled in a structured dietary counselling program. At 12-month follow-up, ALT had normalised, LSM decreased to 8.4 kPa, and HbA1c improved to 6.8%.
Resmetirom, GLP-1 Agonists, and Lifestyle: How to Layer the Treatment
Resmetirom (Rezdiffra) is a liver-directed, selective thyroid hormone receptor-β (THRβ) agonist. The MAESTRO-NASH trial published in NEJM demonstrated that resmetirom 100 mg daily achieved NASH resolution without fibrosis worsening in approximately 30% of patients (vs. 10% placebo) and fibrosis improvement by at least one stage in 26% (vs. 14% placebo) at 52 weeks. These are modest but clinically meaningful numbers - and they represent the first drug to clear an FDA-mandated histological endpoint. Resmetirom is indicated for adults with non-cirrhotic NASH and moderate-to-advanced liver fibrosis (F2–F3). It is not approved for compensated or decompensated cirrhosis.
GLP-1 receptor agonists - semaglutide in particular - do not yet have FDA approval specifically for NASH, but the weight of evidence supports their use as a complementary strategy. The LEAN trial and subsequent data from semaglutide trials show NASH resolution rates of 59% (semaglutide 0.4 mg daily) versus 17% in placebo - though fibrosis regression was not statistically significant in phase 2. A phase 3 semaglutide NASH trial is ongoing. In practice, for patients with NASH and comorbid obesity or T2DM, a GLP-1 agonist serves dual metabolic and hepatic purposes and represents excellent standard-of-care prescribing right now.
Lifestyle intervention remains foundational. A sustained 7–10% body weight reduction is associated with NASH resolution in approximately 50% of patients and fibrosis regression in 20–40%. The challenge is durability - fewer than 10% of patients achieve and maintain this threshold without pharmacological support. Structured dietary programs (Mediterranean or low-carbohydrate dietary patterns) combined with 150+ minutes/week of moderate aerobic exercise are the evidence-based standard.
A Frequently Overlooked Point: Alcohol Thresholds and Competing Diagnoses
Many clinicians under-screen for metabolic-associated steatotic liver disease in patients who report low-level alcohol use - and this creates diagnostic confusion that delays appropriate treatment. The formal MASLD criteria specify alcohol consumption of ≤ 140 g/week in women and ≤ 210 g/week in men, alongside at least one cardiometabolic risk factor. Patients exceeding these thresholds are classified as MetALD - a distinct category that may coexist with metabolic drivers but requires separate management consideration. Failing to quantify alcohol carefully means some MASLD patients get labelled as ALD and do not receive the metabolic intervention that would change their disease trajectory. The AUDIT-C questionnaire takes 60 seconds and belongs in every fatty liver clinic workflow.
Bottom Line for Clinical Practice
Screen by FIB-4 first. A FIB-4 < 1.30 in patients under 65 makes advanced fibrosis unlikely - monitor and optimise metabolic risk. FIB-4 > 2.67 warrants VCTE or biopsy before treatment decisions.
Resmetirom is indicated for F2–F3 NASH - not steatosis alone, not cirrhosis. Histological confirmation is required under current prescribing guidance; confirm your institution's protocol.
Use GLP-1 agonists when metabolic comorbidity is present. Semaglutide or tirzepatide in patients with T2DM or obesity with NASH is guideline-concordant and hepatically beneficial even ahead of specific NASH approval.
Target 7–10% weight loss as the primary lifestyle goal. Frame it in measurable, time-bound terms - vague dietary advice does not move fibrosis scores.
Reclassify your patients using MASLD terminology and document cardiometabolic risk factors - this shapes prognosis communication, screening for hepatocellular carcinoma, and eligibility for future trials.
The next time a patient like this sits across from you - elevated ALT, indeterminate FIB-4, metabolic risk factors stacked up - don't send them away with a generic weight loss leaflet. Walk GastroAGI through the clinical details: fibrosis stage, metabolic profile, comorbidities, current medications. It will return a reasoned, evidence-anchored management plan in seconds.